Anti-Alkaline Phosphatase, Tissue Non-Specific antibody,Abcam,AB203106

Host

Rabbit

Reactivity

Mouse, Rat

Application

WB

Platform ID

BAB636517527

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-Alkaline Phosphatase, Tissue Non-Specific antibody
Cat. No.AB203106
HostRabbit
IsotypeIgG
ReactivityMouse, Rat
ApplicationWB
ClonalityPolyclonal
Concentration1 mg/mL Batch dependent concentration
ImmunogenSynthetic Peptide within Mouse Alpl aa 50-100 conjugated to Keyhole Limpet Haemocyanin. The exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.02% Proclin 300 Constituents: 50% Glycerol (glycerin, glycerine), 48.98% TBS, 1X, 1% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Alkaline phosphatase that metabolizes various phosphate compounds and plays a key role in skeletal mineralization and adaptive thermogenesis (PubMed : 10620060, PubMed : 11028439, PubMed : 14982838, PubMed : 23942722, PubMed : 33981039). Has broad substrate specificity and can hydrolyze a considerable variety of compounds : however, only a few substrates, such as diphosphate (inorganic pyrophosphate; PPi), pyridoxal 5'-phosphate (PLP) and N-phosphocreatine are natural substrates (PubMed : 19874193, PubMed : 23942722, PubMed : 33981039). Plays an essential role in skeletal and dental mineralization via its ability to hydrolyze extracellular diphosphate, a potent mineralization inhibitor, to phosphate : it thereby promotes hydroxyapatite crystal formation and increases inorganic phosphate concentration (PubMed : 10620060, PubMed : 11004006, PubMed : 11028439, PubMed : 12082181, PubMed : 14982838, PubMed : 32035618, PubMed : 9056646). Acts in a non-redundant manner with PHOSPHO1 in skeletal mineralization : while PHOSPHO1 mediates the initiation of hydroxyapatite crystallization in the matrix vesicles (MVs), ALPL/TNAP catalyzes the spread of hydroxyapatite crystallization in the extracellular matrix (PubMed : 20684022, PubMed : 26457330). Also promotes dephosphorylation of osteopontin (SSP1), an inhibitor of hydroxyapatite crystallization in its phosphorylated state; it is however unclear whether ALPL/TNAP mediates SSP1 dephosphorylation via a direct or indirect manner (PubMed : 23427088). Catalyzes dephosphorylation of PLP to pyridoxal (PL), the transportable form of vitamin B6, in order to provide a sufficient amount of PLP in the brain, an essential cofactor for enzymes catalyzing the synthesis of diverse neurotransmitters (PubMed : 7550313). Additionally, also able to mediate ATP degradation in a stepwise manner to adenosine, thereby regulating the availability of ligands for purinergic receptors (PubMed : 19874193, PubMed : 23825434, PubMed : 23942722, PubMed : 32028019). Also capable of dephosphorylating microbial products, such as lipopolysaccharides (LPS) as well as other phosphorylated small-molecules, such as poly-inosine : cytosine (poly I : C) (By similarity). Acts as a key regulator of adaptive thermogenesis as part of the futile creatine cycle : localizes to the mitochondria of thermogenic fat cells and acts by mediating hydrolysis of N-phosphocreatine to initiate a futile cycle of creatine dephosphorylation and phosphorylation (PubMed : 33981039). During the futile creatine cycle, creatine and N-phosphocreatine are in a futile cycle, which dissipates the high energy charge of N-phosphocreatine as heat without performing any mechanical or chemical work (PubMed : 33981039). See full target information Alpl

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.